Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Covidien (COV) Stock Price

News stories about Covidien (NYSE:COV) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Covidien earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave press coverage about the healthcare company an impact score of 46.0733408640808 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Covidien (COV) opened at $106.71 on Friday. The company has a market cap of $48,980.00, a price-to-earnings ratio of 27.43 and a beta of 1.01. Covidien has a 1-year low of $65.97 and a 1-year high of $108.57.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Covidien (COV) Stock Price” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://ledgergazette.com/2018/01/13/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-covidien-cov-share-price.html.

Covidien Company Profile

Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company’s brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries.

Insider Buying and Selling by Quarter for Covidien (NYSE:COV)

Receive News & Ratings for Covidien Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covidien and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply